Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 22,529 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 22,529 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,117,663.69. Following the transaction, the chief financial officer directly owned 132,337 shares in the company, valued at approximately $6,565,238.57. This represents a 14.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

James William Rogers also recently made the following trade(s):

• On Wednesday, August 19th, James William Rogers sold 26,313 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total value of $1,578,780.00.
• On Thursday, June 25th, James William Rogers sold 11,529 shares of Tempus AI stock. The shares were sold at an average price of $55.00, for a total value of $634,095.00.

Tempus AI Stock Up 8.8%

TEM opened at $66.65 on Friday. Tempus AI, Inc. has a 52 week low of $40.77 and a 52 week high of $104.32. The business has a 50 day moving average price of $52.44 and a two-hundred day moving average price of $51.21. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. The company has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s revenue was up 21.6% on a year-over-year basis. During the same period last year, the business posted ($0.22) EPS. As a group, research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on TEM. HC Wainwright lowered their price objective on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Piper Sandler reduced their target price on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research note on Tuesday, August 4th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Finally, BTIG Research lifted their target price on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a report on Thursday. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Tempus AI currently has an average rating of “Hold” and an average price target of $65.69.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and reaffirmed a “Buy” rating. The new target implies approximately 20% upside from the referenced price and provides a direct catalyst for buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investors are increasingly focused on Tempus AI’s approximately $1.5 billion all-stock acquisition of Personalis. Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Reported progress involving Moderna and Merck in cancer vaccines has improved sentiment toward genomic-data providers and made Tempus’ Personalis strategy appear more timely. The benefit to TEM is indirect, but the developments support the company’s oncology growth narrative. Tempus AI and cancer vaccine developments
• Positive Sentiment: Call-option volume reached 40,671 contracts, about 57% above typical activity, signaling bullish speculation and potentially amplifying momentum.
• Neutral Sentiment: TEM’s move above key moving averages has been described as a possible short squeeze. This can support further gains, but it also raises volatility and reversal risk. Tempus AI technical rally
• Negative Sentiment: Several executives sold shares, including CEO Eric Lefkofsky, CFO James William Rogers and EVP Andrew Polovin. The sales totaled substantial amounts and reduced their holdings, which can concern investors. However, the transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Institutional Trading of Tempus AI

A number of institutional investors have recently added to or reduced their stakes in TEM. JPL Wealth Management LLC acquired a new position in Tempus AI during the third quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in shares of Tempus AI during the 4th quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Tempus AI during the 3rd quarter valued at approximately $38,000. Whittier Trust Co. boosted its stake in shares of Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Tempus AI by 88.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock worth $44,000 after acquiring an additional 325 shares in the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.